Department of Urology, University-Hospital of Parma.
Department of Urology, University of Verona.
Acta Biomed. 2021 Sep 2;92(4):e2021191. doi: 10.23750/abm.v92i3.11475.
External Beam Radiation Therapy (EBRT) is one of the option available for the treatment of clinically localized prostate cancer. In patients with radiorecurrent localized prostate cancer, Androgen Deprivation Therapy (ADT) is one of the most common therapeutic strategies. However, in the last decades, other salvage treatment options have been investigated, such as brachytherapy, cryoablation and High Intensity Focused Ultrasound (Hifu).
The oncologic outcome of Hifu in a salvage setting after EBRT failure was investigated. We reviewed the literature from 2005 to 2020 in order to report the oncologic outcome of the technique.
A total of 1241 patients were analyzed, with a mean age of 68.6 years and a PSA value of 5.87 ng/mL before treatment. Mean follow-up was 24.3 months after treatment, ranging from 3 to 168 months.
Our review of the literature revealed that salvage Hifu is effective in the treatment of radiorecurrent clinically localized prostate cancer, with an overall survival of 85.2% at 5 years.
外照射放射治疗（EBRT）是治疗临床局限性前列腺癌的选择之一。对于放射性复发性局限性前列腺癌患者，雄激素剥夺疗法（ADT）是最常见的治疗策略之一。然而，在过去几十年中，已经研究了其他挽救性治疗选择，例如近距离放射治疗、冷冻消融和高强度聚焦超声（Hifu）。
研究了 EBRT 失败后挽救性 Hifu 的肿瘤学结果。我们回顾了 2005 年至 2020 年的文献，以报告该技术的肿瘤学结果。
共分析了 1241 例患者，治疗前的平均年龄为 68.6 岁，PSA 值为 5.87ng/ml。治疗后平均随访 24.3 个月，随访时间 3 至 168 个月。
我们对文献的回顾表明，挽救性 Hifu 治疗放射性复发性临床局限性前列腺癌有效，5 年总生存率为 85.2%。
